Comparative impact of standard approach, fdg pet and fdg dual-head coincidence gamma camera imaging in preoperative staging of patients with non-small-cell lung cancer

Nuclear Medicine Communications

Volumn 24, Issue 12, 2003, Pages 1215-1224

  Delahaye, N ^a   Crestani, B ^a   Rakotonirina, H ^a   Lebtahi, R ^a   Sarda, L ^a   Girard, P ^a   Charpentier, E ^a   Fery lemonnier, E ^a   Syrota, A ^a   Aubier, M ^a   LE GULUDEC, D ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Dual head coincidence imaging; Fluorodeoxyglucose; Lung cancer; PET

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INSTRUMENTATION; LABORATORY DIAGNOSIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; REPRODUCIBILITY; SCINTILLATION CAMERA; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; CANCER DIAGNOSIS; CANCER INVASION; CANCER SIZE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; FOLLOW UP; HISTOPATHOLOGY; INTERMETHOD COMPARISON; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RADIOSENSITIVITY; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4344593960     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200312000-00003     Document Type: Article

References (21)

1. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914-924.
2. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16: 2142-2149.
3. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest 2000; 117: 773-778.
4. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-446.
5. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999; 213: 530-536.
6. Pieterman RM, Van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: 254-261.
7. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212: 803-809.
8. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37: 1428-1436.
9. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small-cell lung cancer: priority for a PET-based strategy after nodale-negative CT results. Eur J Nucl Med 2000; 27: 1598-1609.
10. Conférence de Consensus. Bilan d'extension conventionnel préthérapeutique du cancer bronchique non à petites cellules. Rev Mal Resp 1992; 9: R317-R322.
11. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol 1985; 144: 261-265.
12. Moutain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
13. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42: 1596-1604.
14. Tatsumi M, Yutani K, Watanabe Y, et al. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 1999; 40: 566-573.
15. Boren EL, Delbeke D, Patton JA, Sandler MP. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies. Eur J Nucl Med 1999; 26: 379-387.
16. Landoni C, Gianolli L, Lucignani G, et al. Comparison of dual-head coincidence PET versus ring PET in tumor patients. J Nucl Med 1999; 40: 1617-1622.
17. Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998; 207: 431-437.
18. Weber WA, Neverve J, Sklarek J, et al. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system. Eur J Nucl Med 1999; 26: 388-395.
19. Deslauriers J, Ginsberg RJ, Piantadosi S, Fournier B. Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer. Chest 1994; 106: 329S-330S.
20. Andre F, Grunenwald D, Pujol JL, et al. Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy. Cancer 2001; 91: 2394-2400.
21. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med l994, 35: 1308-1312.